This page shows the latest Extavia news and features for those working in and with pharma, biotech and healthcare.
to Novartis’ Extavia which had been the only recommended drug after a first cost appraisal.
Multiple sclerosis patients in England and Wales look set to have just one interferon therapy option after draft NICE guidance backed routine funding for Novartis’ Extavia and rejected other drugs. ... The MS Society said the proposals won’t affect
Rebif generated global sales of $2.1bn in 2009, and Extavia achieved $20m in the first quarter. ... Novartis received approval last year to sell Extavia and currently pays royalties to Bayer.
Extavia received EU approval in May 2008 to treat early and relapsing forms of MS. ... Extavia is reportedly the "first in a new planned portfolio" of MS medicines for Novartis.
Novartis has announced that the European Commission has granted approval for its new multiple sclerosis (MS) treatment, Extavia, and has said it intends to continue broadening its product range in this ... Extavia is the same as the MS treatment Betaferon
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Indigenus presentation of the launch campaign rolled out for Extavia in Summer 2011.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...